Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This study will look at different dose levels and regimens of everolimus combined with weekly
trastuzumab and vinorelbine therapy in patients with HER-2 overexpressing metastatic breast
cancer.